INTRODUCTION
Osteoarthritis is a multifaceted whole joint disease involving degeneration of articular cartilage, subchondral bone sclerosis and synovial inflammation with these combine symptoms culminating in joint pain and disability [1] . Impacting more than 10% of the US population, osteoarthritis poses an enormous economic burden comprised of medical care costs, lost wages, and reduced economic productivity, with significant impact on the quality-of-life of its sufferers [2, 3] . Despite its clinical and financial ramifications, there are currently no approved disease modifying osteoarthritis drugs available, with symptom palliation the only alternative [4] . Osteoarthritis is now recognized as a disease of complex cause, including age, injury, genetics, sex, and obesity as central contributing factors [5] . A commonality shared by many of these contributors is chronic systemic inflammation [6] [7] [8] [9] [10] [11] , and emerging research has firmly linking the inflammation of obesity and osteoarthritis initiation and progression [11,12,13 && ]. The microbiome is the totality of the microbial ecosystems that exist within and on the human body, including both organisms and their secreted products [14] [15] [16] . The microbiome is a crucial component of the holobiont, and has significant ramifications for human health [17] . A growing understanding of the gut microbiome ascribes to it both endocrine and immunological function [18, 19] . The number of bacterial cells in the human microbiome likely exceeds the number of host cells, with this ratio ranging anywhere from 1 : 1 up to estimates that bacterial cells outnumber human cells by a factor of 100 [20, 21] . Wet mass of the microbiome has been calculated to equal that of the human kidney, supporting the notion that it could fundamentally serve an endocrine-like regulatory role.
Defining a healthy microbiome is a difficult endeavor owing to the large variations in what could be considered 'normal' caused by diurnal rhythms, immune status, diet, genetics, and many other variables [22] [23] [24] [25] [26] . However, shifts in the microbiome have an established role in numerous diseases, including amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, rheumatoid arthritis (RA), Crohn's disease, type 2 diabetes, metabolic syndrome, and osteoporosis [27-32,33 && ]. A common factor in many of these diseases is chronic local and systemic inflammation, and it is now understood that the gut microbiome contributes to inflammation by inducing the production of proinflammatory cytokines by host immune cells and by production of inflammatory bacterial metabolites [34] . Given that osteoarthritis is now understood to involve an inflammatory component, particular in the context of obesity [35, 36] , and as it is established that the gut microbiome is a regulator of inflammation [37] [38] [39] , studies investigating the connections between the gut microbiome and the degenerative processes of osteoarthritis are crucial. In this review we will provide a state of the field assessment on work connecting the gut, joint, and osteoarthritis.
Most of our knowledge about the role of the gut microbiome in the development of inflammationdriven diseases has been generated outside the context of the skeletal system. Recently, however, a number of studies have provided data suggesting a role for the gut microbiome in bone homeostasis, RA, and most recently in osteoarthritis initiation and progression. In the context of osteoarthritis, these studies have used various rodent models of joint degenerative disease such as high-fat diet (HFD)induced obesity, mechanical over-loading, surgical induction, and genetically prone rodent models; in all cases potential contributions of the gut microbiota to progression of osteoarthritis have been suggested. Table 1 provides a summary of the key published works that contribute to the current state of the field. Hinting at human relevance, a couple studies have suggested that patients diagnosed with osteoarthritis possess a quantifiable dysbiosis in the gut microbiome, supporting the concept that there is an osteoarthritis-associated microbial shift that may be pathogenic. As obesity and metabolic syndrome are known to be caused by gut microbiome dysbiosis and are important risk factors in the development of osteoarthritis [6, 40] , it follows that among all causes of osteoarthritis, potential causation in this context has been the most extensively investigated. Studies have shown that human obesity is associated with increased osteoarthritis risk in both weight bearing and nonweight bearing joints [41] , suggesting the possibility of systemic players in the development of the osteoarthritis of obesity. In addition, studies on obesity in conjunction with other causes of osteoarthritis, such as injury [destabilization of the medial meniscus (DMM) or intra-articular fracture surgery] have reported an enhanced osteoarthritis severity, thus suggested a synergic effect of obesity [41, 42] .
STUDIES CONNECTING GUT MICROBIOME AND OSTEOARTHRITIS
Study of a potential gut microbiome-joint axis in homeostasis and disease is a nascent area of study. Early work involved rodent models of osteoarthritis and in humans diagnosed with osteoarthritis, revealing a correlation between increased levels of circulatory inflammatory markers including bacterially produced lipopolysaccharides (LPS) that correlate with osteoarthritis severity, suggesting that microbiome-derived proinflammatory metabolites are players in osteoarthritis [43, 44] . In a study of rats fed high-fat/high-sugar diet for 28 weeks, Collins et al. showed increased cartilage damage in obese animals and established a direct correlation
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Joint protective nutraceuticals may act by shifting the gut microbiome. ] showed a decline in the severity of posttraumatic osteoarthritis in the germ-free situation; this provided evidence for a role of the gut microbiome in osteoarthritis pathogenesis in this model. Suggesting relevance in humans, in 25 patients with knee osteoarthritis, Huang et al. [44] established a link between serum and synovial fluid LPS levels with activated macrophages in the knee joint capsule and synovium, joint space narrowing, osteophyte formation, and increased WOMAC scores (i.e., worse symptoms). Connecting these LPS-osteoarthritis associations with a possible dysbiosis in the gut microbiome occurred in a study of the Rotterdam cohort. In 1444 participants enrolled in the Rotterdam study-III with hip and/ or knee osteoarthritis, an association between increased WOMAC score and abundance of microbes in the proinflammatory Streptococcus taxa was identified [46 & ]. This study further established human relevance, prompting the field to more carefully examine the role of a dysbiotic community or individual taxa as pathogenic in osteoarthritis.
To investigate the role of metabolic dysfunction in the absence of overt obesity on gut-joint associations and the involvement of individual taxa in this context, Guss et al. used a murine genetic model of metabolic syndrome (Toll-like receptor-5 deficiency) in combination with osteoarthritis-inducing mechanical overloading (2 or 6 weeks). The authors compared the impact of the metabolic disorder in this context to previously studied HFD-induced osteoarthritis models. Evaluation of histological changes in the cartilage indicated more severe osteoarthritis in the HFD-fed group; in this group they detected metabolic irregularities, increased body fat, systemic inflammation and the expected gut microbiome dysbiosis which included an increased abundance of Firmicutes. They concluded that while metabolic irregularities were observed in Toll-like receptor-5 deficient mice, alone they were not sufficient to induce osteoarthritis. Rather, they showed that increased levels of LPS in HFD-fed mice was associated with higher OARSI scores and a dysbiosis involving expansion of Firmicutes, suggesting an association between microbial components and development of osteoarthritis [47] .
In an article providing evidence that gut microbiome dysbiosis in obesity is more than just associated with osteoarthritis, Schott et al. [13 && ] examined microbial community shifts in HFD-fed obese mice with an overlay of DMM injury to synchronize initiation of disease. Histological evaluation showed increased cartilage degradation in HFD-fed obese mice and 16S sequencing confirmed a gut dysbiosis. Importantly, when HFD-fed obese mice were supplemented with the indigestible fiber oligofructose, the obese gut dysbiosis was mitigated and osteoarthritis progression was essentially halted. Bifidobacterium pseudolongum, a species with known antiinflammatory properties [48] that was lost in HFD-fed mice, was restored following oligofructose supplementation [13 && ]. Conversely, proinflammatory Peptococcaceae and Peptostreptococcaceae family members that were present in the obese cohort were completed ablated in oligofructose-supplemented mice. These findings provided the first published evidence that shaping of the microbial community with an indigestible prebiotic fiber, lacking direct effects on host biology, could be disease modifying in osteoarthritis; implication from the work indicate a causal link between gut microbiome dysbiosis and osteoarthritis.
Consistent with the Schott et al. findings, HFDfed rats supplemented with oligofructose also showed delayed development of obesity-associated osteoarthritis [49 && ]. In this report, Rios et al. demonstrated that a maximum protection could be achieved by combining the supplement with exercise. Paralleling the Schott et al. study, 16S sequencing demonstrated an increase in Bifidobacterium and Roseburia and a decrease in Clostridium leptum and Akkermansia muciniphila levels as a result of oligofructose supplementation [49 && ]. Another recent study in a guinea pig model of spontaneous osteoarthritis showed that the oral administration of a lyophilized inactivated culture of Bifidobacterium longum CBi0703 reduces cartilage structural lesions and cartilage degradation markers, providing an overall joint protective effect [50 & ]. Future studies on microbes from the Bifidobacterium taxa and their metabolites may be important in establishing a gut-joint axis and may represent a subset of new approaches to treat osteoarthritis that involve targeting the gut microbiome.
NUTRACEUTICALS MAY IMPROVE OSTEOARTHRITIS OUTCOMES VIA EFFECTS ON THE GUT MICROBIOME
Glucosamine, chondroitin sulfate, and undenatured type 2 collagen (UT2C) are nutraceuticals marketed as dietary supplements supportive of joint health. In the US alone, these compounds make up a multibillion-dollar industry that spans both human and animal use [51] . In the first major article detailing the protective effects of nutraceuticals on joint disease, Trentham et al. [52] demonstrated that oral consumption of rooster comb type 2 collagen had beneficial effects on biological, structural, and pain outcomes in patients with RA flare. Although this provocative finding was met with broad skepticism because of uncertainty regarding mechanism of action, it was an important early piece of evidence for use of cartilage component-based nutraceuticals to treat joint arthropathies. Various preclinical experiments have also supported the notion that oral supplementation with 'joint protective' nutraceuticals is effective at mitigating osteoarthritis. For example, Dar et al. [53] demonstrated that daily oral consumption of hydrolyzed type I collagen is chondroprotective in murine post traumatic osteoarthritis. Similarly, Bagi et al. [54] demonstrated that oral supplementation with undenatured native chicken type 2 collagen reduced joint degeneration in a rat model of posttraumatic osteoarthritis. As oral supplements composed of cartilage and soft tissue matrix components are the only agents with clinical data supporting positive patient-reported functional improvement in osteoarthritis [55] [56] [57] , we and others have speculated that positive results may be due to an unappreciated action of these agents as prebiotics that can affect the gut microbiome.
Suggesting a potential mode of biological action that involves shaping of the gut microbiome, several studies have documented microbial shifts is response to chondroitin sulfate [58] [59] [60] . In the Liu et al. [58] study particularly, supplementation was associated with reductions in inflammatory Proteobacteria and increases in a Bacteroidetes taxa that blocks stressinduced intestinal inflammation. These shifts suggest a potential mode of action in osteoarthritis. To address this possibility, we supplemented mice on a chow-based diet with two popular joint-protective nutraceuticals (see Supplementary data, http://links. lww.com/COR/A48). Mice were supplemented daily with either 0.31 mg/g of body weight of glucosamine or 2 mg/g of body weight of UT2C to examine their joint protective capabilities and to examine changes in the gut microbiome. In chow fed mice, osteoarthritis was initiated by trauma (DMM surgery), and as expected, we observed degenerative change to the cartilage in injured joints compared with shamoperated controls. In mice given the same injury but fed a diet supplemented with either glucosamine or UT2C, we observed a deceleration of degenerative change (Fig. 1a-c) , evidenced by a general improvement in OARSI scores of mice supplemented with glucosamine (2.16 AE 0.98) or UT2C (1.88 AE 0.84) compared with the vehicle control (2.54 AE 0.52). Histomorphometric analysis of joint cartilage revealed increased tibia total cartilage area, tibia uncalcified cartilage area, and number of Safranin O þ chondrocytes all in both glucosamine and UT2C supplemented mice compared with the vehicle control ( Fig. 1d and e ).
16S sequencing of DNA extracted from fecal pellets harvested from these mice revealed changes in the abundance of Bacteroidetes, Actinobacteria, and Firmicutes, among others ( Fig. 2a ). Firmicutes and Bacteroidetes are typically the dominant phyla of the vertebrate microbiome [61] , and an increase in Firmicutes and decrease in Bacteroidetes has been associated with proinflammatory states in both humans and mice [62, 63] . The change in the ratio may be linked with inflammation as an effect of both different responses to caloric intake and increased ability to extract calories from food [64, 65] . Related to this, we found an increased Bacteroidetes/Firmicutes ratio in the microbiome of mice fed either glucosamine or UT2C compared with the vehicle control ( Fig. 2a ), consistent with a potential anti-inflammatory shift.
Numerous differences at the level of individual operational taxonomic units (OTUs) were found when either glucosamine or UT2C supplemented mice were compared with the vehicle control (Fig. 2b) . The family Rikenellaceae and the Bacteroidales family S24-7 were significantly increased in mice fed glucosamine, while the supplement caused the opposite trend in an Oscillospira species (Fig. 3a) . Dietary supplementation with UT2C produced even more changes in the abundance of individual OTUs than glucosamine when compared with the vehicle control. As with glucosamine, UT2C increased the abundance of S24-7 and decreased the amount of Oscillospira (Fig. 3b ). Both Lactobacillus and Turicibacter levels were increased in mice given UT2C compared with vehicle control, and certain Clostridiales taxa decreased as well (Fig. 3b ). Significantly, Rikenellaceae family members are reduced in proinflammatory models of induced colitis [66] . Their increased abundance in mice fed glucosamine may suggest that this family can contribute to a lower inflammatory state. The absence of a change in Rikenellaceae in the UT2C-fed mice may indicate a glucosamine-specific effect. We also found Turicibacter to be significantly increased in mice fed UT2C compared with vehicle control or glucosamine. This genus has been found to be expanded in RA [67] although it has also been shown to be reduced in HFDs [68] .
The family S24-7, also known as Muribaculaceae and Candidatus Homeothermaceae, is a dominant member of the murine gut microbiome [61, 69] . Like Rikenellaceae, they have also been shown to decrease in colitis [66] , and here we demonstrate their increase with both glucosamine and UT2C supplementation. Recent work has shown that HFD, a cause of systemic inflammation, is associated with a decrease in both Rikenellaceae and S24-7 [70] . In addition, S24-7 are most often found in herbivores or omnivores with a high percentage of plant material in the diet; they ferment glucans to yield shortchain fatty acids that can have anti-inflammatory effects [61, 71] . The biological impact of changes in S24-7 may be more complex than a simple antiinflammation as they are increased in diabetessensitive mice fed a HFD as well as after remission of induced colitis [61] .
Nutraceuticals are long standing supplements implicated in joint health whose efficacy has been difficult to define with biological measures. Defining the mechanism of action has been problematic due to their relative inability to reach the joint. New findings presented here reveal that mice fed either glucosamine or UT2C supplements demonstrate changes in both joint health and microbiome. Tibia cartilage, uncalcified cartilage, and Safranin O þ chondrocytes are all increased in supplemented mice compared with vehicle controls. Global changes in phyla, Bacteroidetes/Firmicutes ratio, and individual OTUs in mice given supplements mirror improvements in the joint. Together, these parallel phenotypes suggest that nutraceuticals may exert beneficial action on joint health through modulation of the gut microbiome; further proof of causal links will require deeper investigation.
CONCLUSION
Emerging research provides compelling evidence of a link between the gut microbiome and development of osteoarthritis. Most of the studies to date have identified interesting associations, with candidate interventions involving indigestible prebiotics providing the best evidence of a causal linkage between the gut and joints. Moving forward, the field must perform deep analysis of causation using fecal microbiota transplant methods and metabolomic study of molecular mediators produced by microbiota that can impact host biology and induce -or protect from -joint degenerative disease. In addition to defining the pathogenic role the gut microbiome plays in osteoarthritis, establishing this connection provides the opportunity for development of new and effective disease modifying osteoarthritis therapeutics. In fact, it is possible that the only commonly used intervention with evidence of improvement in osteoarthritis symptoms, namely nutraceuticals, act indirectly via effects on the gut niche.
